Skip to main content

Table 1 Study characteristics of studies investigating the prognostic relevance of HPV-16

From: Prognostic implication of human papillomavirus types in cervical cancer patients: a systematic review and meta-analysis

Author Year Country Total number of patients Mean age Clinical stage Treatment Number of patients with HPV-16 positive Number of patients with HPV-18 negative Median DFS Median PFS Median OS
Yat Ming Lau 2015 Hong Kong, China 236 54.4 I-III radiotherapy+/−chemotherapy 142 94 73.2% vs. 81.2%, HR: 1.54, 95% CI = 0.93–2.56 NA 71.6% vs. 81.7%, HR: 0.99, 95% CI = 0.64–1.55
Dong Hang 2017 China 306 48 I-IV surgery alone, surgery plus adjunctive chemotherapy, radiotherapy or chemoradiotherapy, concurrent chemoradiotherapy, chemotherapy or radiotherapy only. 186 120 NA NA HR: 0.36, 95% CI = 0.18–0.74, P = 0.005
Mamiko Onuki 2018 Japan 137 49.2 I-IV Surgery+radiotherapy 59 78 NA NA HR: 0.42, 95% CI = 0.15–1.04, P = 0.06
Byoung Hyuck Kim 2019 Korea 298 48 I-IV radiotherapy 164 127 NA 77.6 vs. 57.7%, P = 0.022 HR: 0.558, 95% CI = 0.326–0.955, P = 0.033
Sun-Hye Yang 2014 Korea 116 NA I-IIA surgery 49 67 NA HR: 1.33, 95% CI = 0.31–5.67, P = 0.70 Not significant
Rossana de Arau ́jo Cata ̃o Zampronha 2013 Brazil 86 40 I Surgery+radiotherapy 30 56 HR: 1.104, 95% CI = 0.243–5.007 NA NA
  1. HPV Human papillomavirus, DFS Disease free survival, HR Hazard ratio, CI Confidence interval, NA Not available, DFS Disease free survival, PFS Progression free survival, OS Overall survival